A Young Boy with L-asparaginase-Induced Seizure

Area of Science:

• Pediatric Hematology
• Neuro-oncology
• Clinical Case Reports

Background:

• L-Asparaginase is a cornerstone therapy for pediatric acute lymphoblastic leukemia.
• It is associated with significant toxicities, including coagulation disorders, CNS thrombosis/hemorrhage, vasculitis, and hypersensitivity.
• Neurological complications like seizures are considered uncommon.

Observation:

• A case report of a pediatric patient undergoing L-asparaginase therapy is presented.
• The patient developed seizures during the treatment course.
• Crucially, the patient showed no evidence of hemorrhagic or thrombotic cerebrovascular events.

Findings:

• Seizures can occur as an uncommon adverse effect of L-asparaginase therapy.
• The absence of cerebrovascular events in this case suggests alternative mechanisms for seizure induction.
• This highlights the need for vigilance regarding diverse neurological presentations during L-asparaginase treatment.

Implications:

• Clinicians should consider seizures as a potential, albeit rare, neurotoxicity of L-asparaginase, even without overt vascular events.
• Further research is warranted to elucidate the precise mechanisms underlying L-asparaginase-induced seizures.
• This case broadens the understanding of L-asparaginase's neurological adverse event profile in pediatric leukemia treatment.